Personalized medicine: when the common becomes the rare
2024
Personalized Medicine: When the Common Becomes the Rare
publication
Author Information
Author(s): Daniel J. O'Connor
Primary Institution: The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom
Conclusion
Personalized medicine is revolutionizing drug development in oncology by shifting the focus from common conditions to smaller, more specific patient cohorts.
Supporting Evidence
- Personalized medicine offers clear advantages for patients in terms of treatment choices.
- The rise of small population research is shifting the traditional paradigm of drug development.
- Smaller subsets of patients will impact clinical program and trial design.
Takeaway
Personalized medicine helps doctors find the best treatment for each patient, even if there are only a few people with a specific type of cancer.
Potential Biases
Decisions may be made with less data, increasing uncertainty.
Limitations
Smaller studies may have more variability and missing data, leading to uncertainty in conclusions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website